ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in San Diego, California, dedicated to developing and commercializing treatments for severe allergic reactions. The company's mission is to empower at-risk patients and caregivers by providing patient-friendly, needle-free treatment options to protect against severe allergic reactions that could lead to anaphylaxis.

The company's primary product is neffy® (epinephrine nasal spray), designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is notable as the first FDA-approved needle-free epinephrine product, utilizing a proprietary composition of epinephrine with an absorption enhancer for intranasal delivery. This innovative approach aims to provide injection-like absorption in a small, portable, and easy-to-use device, addressing a critical market need for alternatives to traditional injectable epinephrine.

ARS Pharmaceuticals has achieved significant milestones, including the commercial launch of neffy, with over 22,500 healthcare providers prescribing the product and more than 90% overall commercial coverage in the U.S. The company has also secured regulatory approvals for neffy in multiple international markets, including Canada, Europe, China, Japan, Australia, and the UK. Led by Co-Founder, President, and CEO Richard Lowenthal, ARS Pharmaceuticals is actively expanding its market presence and is conducting a Phase 2b trial for intranasal epinephrine for chronic spontaneous urticaria, with interim data anticipated in the second half of 2026. The company maintains a strong financial position, with sufficient cash to fund operations through cash-flow breakeven.